Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Oct 09, 2019

SELL
$2.22 - $3.39 $2,886 - $4,407
-1,300 Closed
0 $0
Q1 2018

May 11, 2018

BUY
$6.7 - $12.95 $8,710 - $16,835
1,300 New
1,300 $14,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Seven Bridge Financial Group, LLC Portfolio

Follow Seven Bridge Financial Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Seven Bridge Financial Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Seven Bridge Financial Group, LLC with notifications on news.